How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

116 results for

DEA Controlled Substance

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. DEA Controlled Substance

DEA Controlled Substance DEA Controlled Substance Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 DEA Controlled Substance DEA (...) Controlled Substance Aka: DEA Controlled Substance , Schedule I Opioid , Schedule II Opioid , Schedule III Opioid , Schedule IV Opioid , Schedule V Opioid , Schedule I Controlled Substance , Schedule II Controlled Substance , Schedule III Controlled Substance , Schedule IV Controlled Substance , Schedule V Controlled Substance From Related Chapters II. Types: Class I (Schedule I Controlled Substance) High abuse potential No accepted medical use Examples III. Types: Class II (Schedule II Controlled

2018 FP Notebook

2. A DEA agent explains how to fight the opioid crisis and mitigate DEA risk

this is important, how we got here, and how to navigate MAT risk- free to help combat opioid dependency — from a lifelong DEA agent. SAMHSA oversees MAT for opioid dependence, while DEA supports their efforts through the regulation and oversight of controlled narcotic substances approved by the Food and Drug Administration (FDA). Sublingual buprenorphine was first approved for clinical use in 2002 by the FDA and in combination with counseling and behavioral therapies, allows qualified physicians the ability (...) dose before a prescription was written. Most providers back then maintained an inventory of buprenorphine in their offices for dispensing and induction. In keeping with requirements under the Controlled Substances Act (CSA), the DEA began conducting buprenorphine recordkeeping inspections of MAT providers starting around 2006. Many of these providers failed the inspections due to a lack of education and understanding regarding recordkeeping requirements for buprenorphine dispensing. As you could

2018 KevinMD blog

3. 10 ways to stay out of the DEA’s crosshairs

an opioid or benzodiazepine prescription to a female patient in exchange for sex. In other instances, the entirety of circumstances involving the physician must be considered. One found the following factors common in many investigations: (1) An inordinately large quantity of controlled substances was prescribed. (2) Large numbers of prescriptions were issued. (3) No physical examination was given. (4) The physician warned the patient to fill prescriptions at different drug stores. (5) The physician (...) action is almost always found as a contributing factor to a physician who gets into trouble. It’s also against federal law ( ). 3. Do not maintain controlled substances in your office if possible — prescribe only. This will mitigate substantial risk due to drug security and recordkeeping requirements. If you do have to maintain controlled substances ensure you keep . 4. Remember the federal definition of a legitimate prescription ( ) which most states copy verbatim: “A prescription for a controlled

2018 KevinMD blog

4. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review

steadily after age 12 and peaks among youth ages 18-23 (White, Evans, Ali, Achara-Abrahams, & King, 2009). Although not every youth who experiments with alcohol or illicit drugs is diagnosed with an SUD, approximately 7-9% of 12-24 year olds in the United States were admitted for public SUD treatment in 2013 (Substance Abuse and Mental Health Services Administration [SAMHSA], 2016). Recovery from an SUD involves reduction or complete abstinence of use, defined broadly as “voluntarily sustained control (...) , availability of drugs or alcohol, and substance-approving norms on campus (Centers for Disease Control [CDC], 2011; Spear & Skala, 1995; Wambeam, Canen, Linkenbach, & Otto, 2014). Given the many social and environmental challenges faced by youth in recovery from substance use, recovery-specific institutional supports are increasingly being linked to 8 The Campbell Collaboration | www.campbellcollaboration.org educational settings. The two primary types of education-based continuing care supports for youth

2018 Campbell Collaboration

5. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic

Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine - American Journal of Obstetrics & Gynecology Email/Username: Password: Remember me Search Terms Search within Search (...) Share this page: Access provided by Volume 221, Issue 1, Pages B5–B28 Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine The workshop was convened at the 38th Annual Pregnancy Meeting of the Society for Maternal-Fetal Medicine in Dallas, TX, January 29–February 2, 2018. x Jeffrey

2019 Society for Maternal-Fetal Medicine

6. DEA Controlled Substance

DEA Controlled Substance DEA Controlled Substance Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 DEA Controlled Substance DEA (...) Controlled Substance Aka: DEA Controlled Substance , Schedule I Opioid , Schedule II Opioid , Schedule III Opioid , Schedule IV Opioid , Schedule V Opioid , Schedule I Controlled Substance , Schedule II Controlled Substance , Schedule III Controlled Substance , Schedule IV Controlled Substance , Schedule V Controlled Substance From Related Chapters II. Types: Class I (Schedule I Controlled Substance) High abuse potential No accepted medical use Examples III. Types: Class II (Schedule II Controlled

2015 FP Notebook

7. Urban and Rural Student Substance Use (Technical Report)

made possible through a financial contribution from Health Canada. The views expressed herein do not necessarily represent the views of Health Canada. The Student Drug Use Surveys Working Group would like to thank Manon Mireault of the Office of Research and Surveillance, Controlled Substances and Tobacco Directorate, Healthy Environments and Consumer Safety Branch, Health Canada for contributing the Youth Smoking Survey data and attending working group meetings in an observer and advisory capacity (...) , and prescription drug abuse. Second, these same outcomes were assessed by each contributing survey using multivariate logistic regressions controlling for sex, grade level (or age), with grades assessed ranging from seven to 12 depending on the survey, and socioeconomic status to determine if they differed as a function of whether students attended school in an area defined as urban or rural. Urban and Rural Student Substance Use Canadian Centre on Substance Abuse • Centre canadien de lutte contre les

2015 Canadian Centre on Substance Abuse

8. Management of Substance Use Disorder

can develop an SUD. In patients with SUD, the mesolimbic pathway responds to cues that addictive substances are available, while its response to the drug itself and to natural rewards diminishes. Simultaneously, repeated substance use impairs the ability to exert inhibitory control. Over time, substance-related cues become more salient, drug craving becomes more compelling, and the individual is less able to inhibit impulses to use substances even as the “high” experienced is diminished.[14 (...) ] Other factors that may affect development of the disease are social environment and age or stage of development. As adolescents’ brains are still developing, including areas governing decision making and self-control, they may be more susceptible to taking risks such as using alcohol or drugs. The prevalence of alcohol and drug use disorders peaks in late adolescence and early adulthood, and starts to decrease after age 26.[27] In addition, those who were affected by substance use earlier

2015 VA/DoD Clinical Practice Guidelines

9. Evidence based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity

or interpersonal problems caused or exacerbated by the effects of the substance Substance dependence (3 criteria or more over 1 year) Substance dependence (3+ in last year) A. tolerance: a need for markedly increased amounts of the substance to achieve intoxication or desired effect or markedly diminished effect with continued use of the same amount of the substance A. a strong desire or sense of compulsion to take alcohol B. difficulties in controlling alcohol-taking behaviour in terms of its onset (...) to incapacitate or kill nontolerant users) B. withdrawal: the characteristic withdrawal syndrome for the substance or the same (or a closely related) substance is taken to relieve or avoid withdrawal symptoms C. D. the substance is often taken in larger amounts or over a longer period than was intended there is a persistent desire or unsuccessful efforts to cut down or control substance use E. F. G. a great deal of time is spent in activities necessary to obtain the substance, use of the substance

2012 British Association for Psychopharmacology

10. Comorbidity of mental disorders and substance use

tiredness, trembling, loss of control of fine movements, slowed reaction time, dizziness, chronic headaches, sinusitis and nosebleeds, spots/rash around the mouth and nose, indigestion and stomach ulcers, liver and kidney damage and hearing loss. Permanent brain injury can occur from the use of solvents. Overdose: More likely to occur with high concentration substances such as butane and occurs after repeated sniffing/inhalations in a single session. Tachyarrhythmias, heart failure and death can (...) with substance-use disorders are able to quit smoking especially if their other substance use is abating. Quitting smoking may also help control their use of other substances**** (102, 107, 108) . 4.1.3 Interactions between tobacco and therapeutic agents used for mental disorders The hydrocarbons in cigarette smoke (not the nicotine) have been shown to increase the body’s ability to metabolise some medications via the cytochrome P450 system, resulting in reduced plasma concentrations of these medications

2008 Clinical Practice Guidelines Portal

11. Overview of Substance-Related Disorders

physical security of and strict record keeping for certain classes of drugs (controlled substances—see table ). Controlled substances are divided into 5 schedules (or classes) on the basis of their potential for abuse, accepted medical use, and accepted safety under medical supervision. The schedule classification determines how a substance must be controlled. Schedule I: These substances have a high addiction liability, no accredited medical use, and a lack of accepted safety. They can be used only (...) under government-approved research conditions. Schedule II to IV: Going from schedule II to IV, these drugs have progressively less addiction liability. They have an accredited medical use. Prescriptions for these drugs must bear the physician’s federal Drug Enforcement Administration (DEA) license number. Schedule V: These substances have the least addiction liability. Some Schedule V drugs do not require a prescription. State schedules may vary from federal schedules. Table Some Examples

2013 Merck Manual (19th Edition)

12. Evidence Brief - Barriers and Facilitators to Use of Medications for Opioid Use Disorder

and the general community despite evidence of their effectiveness and guidelines from the Veterans Affairs/Department of Defense (DoD), Centers for Disease Control & Prevention (CDC), and the Key Findings · We did not identify VHA studies on barriers or facilitators to use of medications for opioid use disorder (OUD) published since 2014. This review focuses on 16 studies that have the most VHA applicability. Most of these studies discussed buprenorphine/naloxone, but not extended-release naltrexone. · The 4 (...) , PsycINFO, EMBASE and Cochrane Central Register of Controlled Trials (CCRT). We used prespecified criteria for study selection, data abstraction, and rating internal validity and strength of the evidence. See our PROSPERO protocol for our full methods. Evidence Brief: Barriers and Facilitators to Use of Medications for OUD Evidence Synthesis Program 2 American Society of Addiction Medicine recommending them as an option for first-line treatment for OUD. Reasons for underutilization of OUD medications

2019 Veterans Affairs Evidence-based Synthesis Program Reports

13. The Foyer model for homeless youth: a systematic mapping review

that addressed the Foyer model. This body of research had the following characteristics: • 56% of the studies were retrieved from grey literature sources and 72% were published as commissioned research reports. • 61% of the studies were cross-sectional, the rest were qualitative. We identified no controlled studies. • All the studies were done in either Australia or the United Kingdom (UK). • The provision of services in the foyers was homogeneous across studies. • There were three categories of studies (...) of four have children of dependent age, one of four suffer from a dual disorder of mental disorder and substance abuse, and 17% are young people un- der 25 years old. It can be hard to escape homelessness. Social welfare schemes, particularly social bene- fits, is the most common mechanism of help. Another support service for young people is the Foyer model (program). The Foyer model is a package of accommodation and in- tegrated support to young people aged between 16 and 24, who are homeless

2018 Norwegian Institute of Public Health

14. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients

the appropri- ate use of opioids. The CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016 details the use of UDT (http:// www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6501e1.pdf ac- cessed 07-14-2017). The recommendations state that prior to starting opioids for chronic pain and periodically during opioid therapy, clinicians should use UDT to assess for prescribed opi- oids, as well as, other controlled substances and illicit drugs that increase risk for overdose when combined with opioids (...) Tests to Monitor Drug Therapy in Pain Management Patients 7 drug testing as a primary prevention, diagnostic, and monitoring tool in the management of addiction or drug misuse in medical practice. While urine drug testing is currently regarded as the stan- dard for adherence monitoring of patients taking controlled substances to manage chronic pain, urine drug testing results are performed/read and interpreted by distinctly different sets of individuals. One group is clinical laboratory physicians

2018 American Academy of Pain Medicine

16. Guidelines on the management of abnormal liver blood tests

follow- up¶ Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses 1c All or none** All case series or none Absolute SpPins and SnNouts†† All or none case series Absolute better-value or worse-value analyses 2a SR (with homogeneity*) of cohort studies SR (with homogeneity*) of either retrospective cohort studies or untreated control groups in RCTs SR (with homogeneity*) of level >2 diagnostic studies SR (...) in the same (preferably blinded) objective way in both exposed and non-exposed individuals and/or failed to identify or appropriately control known confounders and/or failed to carry out a sufficiently long and complete follow-up of patients. Poor-quality case–control study: one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded) objective way in both cases and controls and/or failed to identify or appropriately control known

2017 British Society of Gastroenterology

17. Abuse-Deterrent Formulations of Opioids: Effectiveness and Value

—Abuse-deterrent Formulations of Opioids: Effectiveness and Value List of Acronyms Used in this Report ADF Abuse-deterrent Opioid Formulation with an FDA label AHRQ Agency for Healthcare Research and Quality CI Confidence interval CDC Centers for Disease Control and Prevention CMS Centers for Medicare and Medicaid Services DEA Drug Enforcement Administration DSM Diagnostic and Statistical Manual ER Extended release ER/LA Extended release/Long acting FDA Food and Drug Administration HCV Hepatitis C (...) saw the ADF designation as potentially smoothing access to necessary medication, as it might reduce the typical level of stigma associated with controlled substances. The importance of ©Institute for Clinical and Economic Review, 2017 Page ES7 Evidence Report—Abuse-deterrent Formulations of Opioids: Effectiveness and Value Return to Table of Contents assessing the total clinical, economic, and social value of ADFs was widely recognized by the different stakeholders as an essential step

2017 California Technology Assessment Forum

18. Management of Opioid Therapy (OT) for Chronic Pain

Clinical Practice Guideline for the Management of Substance Use Disorders. Available at: http://www.healthquality.va.gov/guidelines/mh/sud/index.asp. V A / D o D Cli ni cal P r a cti ce G ui d el i n e f o r O p ioid T h e r a p y for Ch r on ic Pa in February 2017 Page 17 of 198 This public health issue, which has been labelled an epidemic,[22] became a focus of the President’s National Drug Control Strategy in 2010 and has since remained a focus. Two main goals introduced in the 2010 strategy (...) presidential memorandum of October 2015 mandated that executive departments and agencies shall, to the extent permitted by law, provide training on the appropriate and effective prescribing of opioid medications to all employees who are health care professionals and who prescribe controlled substances as part of their federal responsibilities and duties. The DoD Opioid Prescriber Safety Training Program, launched accordingly, includes modules on pain management and opioid prescribing safety, the recent

2017 VA/DoD Clinical Practice Guidelines

19. Mitochondrial Function, Biology, and Role in Disease

of mitochondrial disease and suggest potential novel therapeutic approaches. Figure 1. Mutations in mitochondrial proteins (either from mutation in mitochondrial DNA [mtDNA] or nuclear DNA [nDNA]) or acquired defects can lead to defects in mitochondrial quality control, which leads to a vicious cycle of more acquired mitochondrial defects and defects in metabolic signaling, bioenergetics, calcium transport, reactive oxygen species (ROS) generation, and activation of cell death pathways. This leads to a vicious (...) be a major source of reactive oxygen species (ROS) that can both contribute to cell death and serve as a signaling molecule (Generation of ROS). Because the generation of ROS can lead to damage to mitochondrial DNA (mtDNA) and proteins, it is important for the mitochondria to have mechanisms to ensure quality control (Mitochondrial Quality Control). Quality control can occur by fission/fusion to allow segregation of damaged mitochondria (Fission/Fusion/Mitochondrial Dynamics), mitophagy to remove damaged

Full Text available with Trip Pro

2016 American Heart Association

20. Functional Family Therapy (FFT) for Young People in Treatment for Non-Opioid Drug Use: A Systematic Review

such as traffic accidents, sexually transmitted diseases, mental problems and suicide as well as social problems including poor academic achievement, delinquency and violent behavior (Deas & Thomas, 2001; Essau, 2006; Rowe & Liddle, 2006; Office of National Drug Control Policy (ONDCP), 2000; Shelton, Taylor, Bonner, & van den Bree, 2009; Nordstrom & Levin, 2007; Lynskey & Hall, 2000). While cannabis, amphetamine, cocaine and other non-opioid drugs remain illegal in most countries, surveys indicate widespread (...) challenge in the field of substance abuse treatment for young people is therefore to establish not only what works best but also what works for different subgroups. In terms of treatment types, there is some documentation of promising individually- based cognitive and motivational therapies (Waldron & Turner, 2008; Kaminer, 2008; Deas & Thomas, 2001; Galanter & Kleber, 2008). Family-based approaches on the other hand may be equally effective. Family therapy encompasses a range of different interventions

2015 Campbell Collaboration

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>